Abstract. Telomeres are nucleoprotein structures at the ends of chromosomes that are composed of a repetitive G rich sequence and telomeric binding proteins. Telomeres prevent the degradation of chromosomal ends and protect against inappropriate recombination. Telomere attrition involves a tumor suppressor pathway that limits the replication of premalignant cells. The loss of telomeric DNA with each round of replication leads to growth arrest accompanied by senescence or apoptosis. Many tumor cells activate the telomerase gene to bypass senescence. Telomerase is a multisubunit ribonucleoprotein that uses an RNA template to catalyze the addition of telomeric DNA to chromosomal ends. Overexpression of the TERT subunit leads to telomere lengthening and extension of the replicative lifespan. Dominantnegative telomerase has been shown to inhibit telomerase activity in many tumor cell lines, and this is associated with telomere shortening and apoptosis. Additionally, pharmacological telomerase inhibitors have been developed which lead to progressive telomere shortening and programmed cell death. In this study, we report a series of human squamous cell carcinoma cell lines that have high telomerase activity and short telomeres. Dominant-negative telomerase expression and pharmacological telomerase inhibition failed to completely inhibit enzymatic activity which was accompanied by the lack of telomere shortening. These cells continued to proliferate and demonstrated fewer responsive genes when treated with a pharmacological telomerase inhibitor. We concluded that some human squamous cell carcinoma cell lines are resistant to telomerase inhibition.
Introduction
Telomeres are nucleoprotein structures at the ends of chromosomes that are composed of a repetitive G rich sequence (TTAGGG in mammals) and telomeric binding proteins (1) . These structures are dynamic and cap the ends of linear chromosomes. These caps prevent the degradation of chromosomal ends and protect against inappropriate recombination. Telomeric binding proteins allow the formation of telomeric loops which in the single-stranded overhangs normally present at telomeres invade an interior segment of duplex telomeric DNA. Telomere attrition involves a tumor suppressor pathway that limits the replication of premalignant cells (2) . Human telomeres lose 50-200 bp of DNA with each population doubling (PD). Telomeres shorten faster in telomerase-deficient cells, suggesting active nucleolytic attack on chromosomal ends in addition to sequence loss due to incomplete telomere replication with each cell division (3) . The loss of telomeric DNA with each round of replication leads to growth arrest accompanied by senescence or apoptosis (4) . Human tumor cells bypass this proliferation block to become a clinically detectable tumor. Many tumor cells activate the telomerase gene to bypass senescence. Telomerase is a multisubunit ribonucleoprotein that uses an RNA template to catalyze the addition of telomeric DNA to chromosomal ends (5) . The telomerase RNA contains a template complementary to the G rich telomeric repeat. The mammalian telomeric protein contains consensus reverse transcriptase motifs. Overexpression of the TERT subunit leads to telomere lengthening and extension of the replicative lifespan (6) .
Mutations in the reverse transcriptase domains of the telomerase catalytic subunit have been shown to have dominantnegative activity (7) . Dominant-negative telomerase (dnTERT) has been shown to inhibit telomerase activity in many tumor cell lines, and this is associated with telomere shortening and apoptosis. Additionally, pharmacological telomerase inhibitors, such as BIBR1532 have been developed which lead to progressive telomere shortening and programmed cell death (8) . In this study, we report a series of human squamous cell carcinoma (SCC) cell lines that have high telomerase activity and short telomeres and are resistant to telomerase inhibition.
Materials and methods
Cell culture and stable transfection. The human SCC and breast cancer cell lines used in this study were purchased from the American Type Culture Collection and cultured in Dulbecco's modified Eagle's medium, 10% fetal bovine serum, and 40 µg/ml gentamicin in a humidified atmosphere of 5% CO 2 at 37˚C. Cultures were treated with 10 µM of the pharmacological telomerase inhibitor, BIBR1532, or 0.1% DMSO vehicle for up to 400 PDs. For some experiments, cells were transfected with 2 µg dnTERT or neomycin resistance plasmid using Lipofectamine according to the manufacturer's recommendations (Invitrogen). Cells were selected in 400 µg/ml G418 over a period of 14 days. Resistant clones were picked for expansion and characterization.
Reverse transcription polymerase chain reaction. RNA was extracted from human SCC and MDA-MB-231 dnTERT or neomycin-resistant clones using a commercially available kit (Qiagen, valencia, CA) and was reverse transcribed using SuperScript II reverse transcriptase according to the instructions of the manufacturer (Invitrogen). cDNA was amplified using specific primers (TERT, 5'-GTGGCCTCTTCGAC GTCTTC-3' and 5'-CAAGAAATCATCCACCAAAC-3'; dnTERT, 5'-GTGGCCTCTTCGACGTCTTC-3' and 5'-CAA GAAATCAgCCACCAAAC-3') in 20 mM Tris-HCl (pH 8.3), 1.5 mM MgCl 2 , 63 mM KCl, 0.05% Tween-20, 1 mM EGTA, 50 µM of each dNTP, and 2.5 U TaqDNA polymerase (Roche Applied Science). Amplification with β-actin cDNA using primers 5'-ACAGGAAGTCCCTTGCCATC-3' and 5'-ACTGG TCTCAAGTCAGTGTACAGG-3' as the internal control was carried out by real-time PCR (iCycler, Bio-Rad) using cycle parameters 94˚C for 25 sec, 55˚C for 1 min, and 72˚C for 1 min.
Telomeric repeat amplification protocol. Cells were lysed in buffer containing 10 mM Tris-HCl, pH 7.5, 1 mM MgCl 2 , 1 mM EGTA, 0.1 mM benzamidine, 5 mM β-mercaptoethanol, 0.5% 3-[(3cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) and 10% glycerol. RNasin (1 µl) was added to each sample to inhibit RNase activity. After 30 min incubation at room temperature, the lysates were centrifuged for 30 min at 12,000 x g and the supernatants were stored at -80˚ C. Protein concentrations were determined by the Bradford method using Bio-Rad protein dye reagent according to the manufacturer's recommendations. Extracts were diluted in lysis buffer and 5 ng of protein was incubated with 100 ng TS primer (5'-AATCCGTCGAGCAGAGTT-3') and 100 ng ACX primer (5'-GCGCGG[CTTACC] 3 CTAACC -3'). An internal control oligonucleotide used for the quantification of telomerase activity (5'-CGTCGAGCAGAGTTAAAAGGCCG AGAAGCGAT-3') was amplified using TS primer and a return primer (5'-ATCGCTTCTCGGCCTTTT-3'). The 50 µl reaction mixture also contained 50 µM of each deoxynucleotide triphosphate and 5 µCi [α-
32 P]-dCTP in 20 mM Tris-HCl, pH 8.3, 1.5 mM MgCl 2 , 63 mM KCl, 0.05% Tween-20, 1 mM EGTA, and 2.5 U TaqDNA polymerase. Following a 30-min incubation at 30˚C, samples were subjected to 30 cycles of PCR at 95˚C for 30 sec, 50˚C for 30 sec, and 72˚C for 1 min. The PCR products were separated on 10% nondenaturing polyacrylamide gels using 0.5X Tris-borate-EDTA running buffer. Gels were dried and exposed to autoradiographic film at -80˚C for 16 h.
Telomeric restriction fragment analysis. Genomic DNA from SCC and MDA-MB-231 cells was digested with HinfI and RsaI restriction enzymes at 37˚C overnight and subjected to electrophoresis on 0.8% agarose gels. After denaturation and neutralization, DNA was blotted to nylon membranes by capillary transfer. Following blocking, membranes were hybridized with a 32 P-end labeled 24-mer telomeric oligonucleotide probe overnight in aqueous hybridization solution at 60˚C. After three washes in 2X SCC, 0.1% SDS at 55˚C, blots were exposed to Kodak XAR film overnight at -80˚C.
Apoptosis analysis. Human SCC and MDA-MB-231 cultures were fixed with 70% ethanol at -20˚C for 30 min and washed with PBS. Cells were incubated with terminal deoxynucleotidyl transferase and fluorescein-conjugated dUTP at 37˚C for 30 min followed by washing in PBS. The percentage of apoptotic cells was determined by flow cytometry.
Gene expression profiling. Total RNA was extracted from BIBR1532-and DMSO-treated SCC lines and normal NHEK control cells using a commercially available kit (RNeasy, Qiagen). The integrity of the ribosomal RNA bands was confirmed by Northern gel electrophoresis. Total RNA (10 µg) was converted to labeled cRNA targets. The biotinylated cRNA targets were then purified, fragmented, and hybridized to GeneChip human genome U133 expression arrays (Affymetrix, Santa Clara, CA, USA) to interrogate transcript abundance in each sample. Affymetrix GCOS software was used to generate raw gene expression scores and normalized to the relative hybridization signal from each experiment. All gene expression scores were set to a minimum value of 2 times the background determined by GCOS software in order to minimize noise associated with less robust measurements of rare transcripts. Data were analyzed by t-test with a value of p<0.005 followed by ratio analysis (minimum 2-fold change).
Results
To determine the effect of telomerase inhibition on human SCC lines, we expressed dnTERT in these cells by stable transfection (7) . As shown in Fig. 1A , dnTERT was expressed at levels similar to those of endogenous telomerase in the human SCC lines. dnTERT expression was not detected in the neomycin-resistant SCC control clones. We also expressed dnTERT in the human breast cancer cell line, MDA-MB-231, which was shown to undergo telomere shortening and apoptosis when telomerase was inhibited (8) . As shown in Fig. 1B , dnTERT expression completely inhibited telomerase activity in MDA-MB-231 clones. However, 20% of telomerase activity was still detectable in SCC clones overexpressing dnTERT when compared to the neomycin-resistant control cells. We concluded that dnTERT failed to completely inhibit telomerase activity in human SCC lines.
We examined telomere length in human SCC clones expressing dnTERT by telomeric restriction fragment analysis. As shown in Fig. 1C , SCC clones expressing dnTERT which were cultured for 100 PDs did not exhibit significant telomere shortening when compared to the neomycin-resistant control cells. Telomere length ranged from 1 to 4 kb in all SCC clones. In contrast, MDA-MB-231 clones expressing dnTERT demonstrated dramatic telomere shortening after 100 PDs. The range of telomere length in dnTERT-expressing MDA-MB-231 clones was <1 to 2.5 kb compared to 8 kb in the neomycinresistant control cells. We concluded that dnTERT did not produce telomere shortening in human SCC lines.
We examined proliferation in human SCC lines expressing dnTERT. As shown in Fig. 1D , we did not detect significant differences in proliferation rates between the dnTERT and neomycin-resistant SCC clones. dnTERT SCC clones were cultured for 400 PDs without detectable decreases in proliferation. In contrast, MDA-MB-231 clones expressing dnTERT had ceased proliferation by 100 PDs while neomycin-resistant MDA-MB-231 cells were highly proliferative. The loss of proliferation in dnTERT-expressing MDA-MB-231 clones was associated with the dramatic induction of apoptosis as determined by TUNEL assay and cell detachment from the culture flasks (Fig. 1E) . In contrast, no increase in apoptosis was observed in the dnTERT-expressing SCC clones. We concluded that dnTERT had no effect on cellular proliferation or apoptosis in human SCC lines.
To replicate these results using a different means of telomerase inhibition, we treated human SCC lines and MDA-MB-231 cells with 10 µM BIBR1532. As shown in Fig. 2A , BIBR1532 treatment completely inhibited telomerase activity in MDA-MB-231 cells. In contrast, 10-20% of telomerase activity was detected in human SCC lines following BIBR1532 treatment. We concluded that BIBR1532 treatment failed to completely inhibit telomerase activity in human SCC lines.
We examined telomere length in human SCC lines treated with BIBR1532 by telomeric restriction fragment analysis. As 
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shown in Fig. 2B , SCC lines treated with BIBR1532 and cultured for 100 PDs did not exhibit significant telomere shortening when compared to the control cells treated with 0.1% DMSO vehicle. Telomere length ranged from 1 to 4 kb in all SCC clones. In contrast, MDA-MB-231 cells treated with BIBR1532 demonstrated dramatic telomere shortening after 100 PDs. The range of telomere length in the MDA-MB-231 cells treated with BIBR1532 was <1 to 2.5 kb compared to 8 kb in the vehicle-treated control cells. We concluded that BIBR1532 treatment did not produce telomere shortening in human SCC lines. We examined proliferation in human SCC lines treated with BIBR1532. As shown in Fig. 2C , we did not detect significant differences in proliferation rates between the BIBR1532-and vehicle-treated SCC lines. SCC lines treated with BIBR1532 were cultured for 400 PDs without detectable decreases in proliferation. In contrast, MDA-MB-231 cells treated with BIBR1532 had ceased proliferation by 100 PDs while the vehicle-treated MDA-MB-231 cells were highly proliferative. The loss of proliferation in BIBR1532 MDA-MB-231 cells was associated with the dramatic induction of apoptosis as determined by TUNEL assay and cell detachment from the culture flasks (Fig. 2D) . In contrast, no increase in apoptosis was observed in the BIBR1532-treated SCC clones. We concluded that BIBR1532 had no effect on cellular proliferation or apoptosis in human SCC lines.
To compare anti-telomerase resistance in SCC lines to their normal cellular counterparts, we performed gene expression profiling on SCC25 cells and the normal stratified squamous epithelial strain NHEK treated with BIBR1532. The expression of 499 genes in NHEK cells was altered by BIBR1532, compared to 140 differentially expressed genes in the SCC25 line (Tables I and II 
Discussion
Our results indicate that human SCC lines are resistant to telomerase inhibition by dnTERT expression and pharmacological treatment. Both methodologies failed to completely inhibit telomerase activity while the control human breast cancer cell line, MDA-MB-231, was completely inhibited.
Telomere length was not shortened in SCC lines by dnTERT or pharmacological inhibition, proliferation was not decreased, and apoptosis was not increased in these cells. Previous studies have demonstrated that telomerase activity in cancer cells can be inhibited by a number of reagents, such as antisense molecules coupled to peptides to increase cellular uptake (9-11). The telomerase inhibitor, telomestatin, was effective in inhibiting activity, inducing telomere shortening, growth inhibition and apoptosis (12) . G quadruplex ligands have been shown to stabilize telomere structure and inhibit access by telomerase (13) . The TERT promoter has been used to transduce antisense ornithine decarboxylase RNA into cells via adenoviral vectors, inhibiting cancer cell proliferation (14) . Newer drugs such as coumarin derivatives have been shown to inhibit telomerase in gastric cancer cells (15) . Previously described telomerase inhibitors, such as GRN163L have anti-cancer effects without effects on normal stem cell populations, which suggests that this drug may be useful in cancer therapy without resulting in stem cell depletion (16) (17) (18) (19) . The DNA damage response following telomerase inhibition is substantially different than that induced by cytotoxic chemotherapy. Pharmacological inhibition of telomerase does not induce cell cycle inhibition and differentiation in SCC lines. Our study indicates that long-term telomerase inhibition is not effective in human SCC lines, suggesting that resistance to this therapy is a common feature of these cells. Future studies are required to determine the mechanisms of this resistance in order to increase the effectiveness of telomerase inhibition in cancer cells.
